Trial in Absentia Under the Bangladesh International Crimes (Tribunals) Act 1973 – EJIL: Talk! – Go Health Pro

Trial in Absentia Under the Bangladesh International Crimes (Tribunals) Act 1973 – EJIL: Talk! – Go Health Pro

Introduction

Following mass student protests and a violent crackdown that killed at least 1,400 people, Sheikh Hasina’s 15-year authoritarian rule as Prime Minister of Bangladesh ended on 5 August 2024 (here, here, here). Amid unprecedented public outrage, she fled to India, and an interim Government led by Nobel Laureate Dr Muhammad Yunus took charge. The violence was largely triggered by the Government’s shoot-on-sight orders to suppress the protests. Legal proceedings under the International Crimes (Tribunals) Act (ICTA) have since been initiated against Hasina and other Bangladesh Awami League (BAL) leaders for alleged crimes against humanity. Although the International Crimes Tribunal (ICT-BD) has requested her extradition from India, Indian authorities have refused, citing carve-out clauses under the extradition treaty. Special Adviser to the Chief Prosecutor, Toby Cadman, has asserted that the trial will proceed in Hasina’s absence, if necessary. However, this post challenges the legality of conducting such trials in absentia, arguing they lack justification under both the ICTA and international criminal law. This argument gains further weight from the fact that the ICTA prescribes death penalty as its maximum punishment. The post will start by exploring the historical background of the ICTA, then move on to examine its core legal provisions and significant judicial decisions, both domestic and international, complemented by a comparative analysis of the well-established jurisprudence of the UN Human Rights Committee (UNHRC) and the European Court of Human Rights (ECtHR). It ultimately argues that, unless the law is reformed to align with international standards, conducting a trial against Hasina and other defendants in absentia would be inconsistent with established legal norms and would undermine fundamental principles of due process.

Read more

At monopoly trial, Zuckerberg redefined social media as texting with friends – Go Health Pro

At monopoly trial, Zuckerberg redefined social media as texting with friends – Go Health Pro

If Meta can convince the court that the FTC’s market definition is wrong and that TikTok is Meta’s biggest rival, then Meta’s market share drops below monopolist standards, “undercutting” the FTC’s case, Big Tech on Trial reported. But are Facebook and Instagram substitutes for TikTok? Although Meta paints the picture that TikTok users naturally gravitated … Read more

Zacks Small Cap Research – DWTX: Interim Data for Phase 2b Trial in 4Q25… – Go Health Pro

Zacks Small Cap Research – DWTX: Interim Data for Phase 2b Trial in 4Q25… – Go Health Pro

By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced that the first patient was dosed in the Phase 2b HALT-CINP (Halneuron Treatment of Chemotherapy-Induced Neuropathic Pain) trial. This is a four-week study that … Read more

Zacks Small Cap Research – IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… – Go Health Pro

Zacks Small Cap Research – IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… – Go Health Pro

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On March 24, 2025, Imunon, Inc. (NASDAQ:IMNN) announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of … Read more

Zacks Small Cap Research – CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. In August 2024, Cadrenal … Read more